Search This Blog

Showing posts with label YSPSAH. Show all posts
Showing posts with label YSPSAH. Show all posts

Thursday, 20 August 2026

YSPSAH Q2-2026 result

 

Let us have a look on the Q2-2026 quarter report released by YSPSAH.




Both the quarter revenue and quarter reported profit jump yoy. While the revenue jump yoy is mainly derived from stronger overseas sales (particularly from Vietnam, Cambodia and Africa), the reported profit jump yoy is mainly attributed to the very weak reported profit in Q2-2025 due to forex loss (during that time, USD is weakening against MYR as Fed reduces interest rate in the US). Recall that YSPSAH's ~30% of revenue is derived from overseas. So, weak USD will drag the reported net profit, as YSPSAH needs to report on the unrealized forex loss. Meaning to say, they still keep the USD received from customer (without converting to MYR). But the value (in terms of MYR) of the USD received is getting lesser -- > so unrealized forex loss.

As I always mention, the reported profit is quite misleading due to non-cash items. Unrealized forex loss is one of the non-cash items. So, it is better to look into the core profit instead. The calculation of core profit would require more work:


From the table above, I purpose highly the foreign exchange item to highlight the remarkable forex loss experienced by YSPSAH in Q2-2025 of ~ RM 7.135 million. The Management tends to combine both realized and unrealized forex loss here. When doing core profit calculation, I tend to consider only the unrealized forex part. Unfortunately, unlike their annual report, the quarter report of YSPSAH does not provide further info on the unrealized forex. But, according to my study, YSPSAH's realized forex part is less significant as compared to the unrealized forex part.

Let us do the core profit calculation as follow:

Q2 2026  (number in '000):
Core profit = reported profit + Adjustment 
Reported profit  = RM4262
Adjustment = + RM 833 (only consider forex part here)

So, core profit = RM 4262 + RM 833 = RM 5095 (number in '000)

Q2 2025  (number in '000):
Core profit = reported profit + Adjustment 
Reported profit  = RM 746
Adjustment = + RM 7135 (only consider forex part here)

So, core profit = RM 746+ RM 7135 = RM 7881 (number in '000)


So, for core profit wise, Q2 2026 is weaker than Q2 2025 !


What has went wrong in this quarter?


If you look at the table above, you would notice that a few categories are highlighted in RED. Did you see that items like cost of sales (raw material cost), selling expenses and admin expenses all went up during Q2 2026?  I believe the surge of selling & admin expenses is due to higher logistic and distribution cost due to Iran war, as YSPSAH needs to export the drugs to other countries. So, more logistic cost is required, and this is understandable during the current condition. However, what has puzzled me is the cost of sales, which is increased by 13.6% (while revenue increases by 8.5% only). By right, as USD is weakening, YSPSAH needs to fork out lesser MYR to buy the API (raw material), which would contribute to lesser cost of sales right? Or, perhaps the cost of API (in terms of USD) has increased even sharper?? I am not too sure though...  Nevertheless, weak USD would translate to lesser MYR received as well, so Management may need to adjust the USD pricing of those exported drugs upward to protect the gross profit margin. Perhaps the adjusted pricing is not sufficient to cover the increased API cost?

So, my conclusion is the weak Q2-2026 result is due to increased cost.

How about DPHARMA, which mainly focuses on domestic sales (> 90 % local)?

Cost of Sales / Revenue %

In general, YSPSAH recorded lower Cost of sales / Revenue % as compared to DPHARMA. Normally, when USD is getting stronger against MYR (hence weaker MYR), DPHARMA would suffer due to high input cost (see FY 2023). However, as USD is weakening nowadays (after Fed cuts rate), the gross profit margin of DPHARMA would increase again. For YSPSAH, they practice natural hedging, so the currency fluctuation does not matter much. The only caveat is the highly fluctuating reported earning (due to unrealized forex loss/gain), where most investors do not like to see.



Admin Expenses / Revenue %

In general, YSPSAH recorded lower Admin expenses / Revenue % as compared to DPHARMA. However, do note that DPHARMA is getting more efficient now in terms of admin cost management, and the ratio is almost on par with YSPSAH.



Sales and Distribution Expenses / Revenue %

DPHARMA spends less in terms of distribution cost (relative to its revenue) as compared to YSPSAH, which I believe so because DPHARMA focuses mainly on local market. Lesser logistic effort is required as compared to YSPSAH.



Core Profit Margin %

While YSPSAH core profit margin is better than DPHARMA from FY2022 to FY 2025, the two recent quarters in FY 2026 (Q2 2026 in particular) have witnessed weaker core profit margin as compared to DPHARMA. I believe it is due to the elevated input and logistic costs experienced by YSPSAH.



Conclusion

Indeed, investing in YSPSAH really test one's patience. Frankly, I have made a wrong move in FY 2023 by buying quite a lot of YSPSAH shares after I noticed that there is a huge capex being spent (RM 31 M to buy a factory + land from Onkio Electronics). Now, this property is merely used for warehouse purpose... So, do not invest only based on huge capex being spent. We must make sure the capex can be used to generate profit for shareholders.

Fortunately, there is a growth story of YSPSAH recently. Management is ready to run the new injection plant II at the end of FY 2026, which is constructed in its current manufacturing facility. This new injection plant II is used to support the older manufacturing facility which is not working properly. According to the management, once the new injection plant II is running, the older manufacturing facility will be renovated.

All the best, YSPSAH!!



Friday, 22 May 2026

YSPSAH Q1-2026 result

 


YSPSAH just released the Q1-FY2026 result a few days ago. Both revenue and profit attributed to shareholders drop yoy. Let us find out the reason from its quarter report.

Picture below shows the segregation of sales from various countries. Obviously, there is a drop in sales from Malaysia (= RM4.5 M). According to the Management, this is due to the drop in revenue from government hospital. Indeed, government hospital would look into cost first during any medication tender. This does not align with the YSPSAH marketing strategy, which is aiming to provide better service so that they could sell the products at slightly higher price.

Interestingly, there is a huge jump in sales in "Other countries" segment. I need to find out more on this.



Now, it is time to work out the core earning (earning from core business i.e. manufacturing and selling of generic drugs, OTC products) of this quarter.

Starting from the reported earning of RM 9.595 M, we adjust the earning based on the table below to get the core earning.

After adjustment, the core earning for Q1 2026 is RM 16.836 M (vs. Q1 2025 of RM 16.939 M).

As a conclusion, the core earning of Q1 2026 is at par with that of Q1 2025, a slight drop in fact, due to slowdown in local sales.






Tuesday, 19 May 2026

YSPSAH 2026 AGM, Bangi Resort Hotel

I attend the AGM of YSPSAH held at Bangi Resort Hotel with my wife today. After all, YSPSAH is my second largest shareholding in my portfolio. Hence, I keep track of this company closely.

We depart from our home at 8:30 AM and arrive at the venue around 9:37 AM. The traffic is terrible.

As I am late for the meeting, I rush into the ballroom after I reach the venue. I ask my wife to park the car for me as I worry that I might miss the Q&A session. 

I got no time to take picture as well.

There is no financial result briefing from the Board, as usual. As soon as I enter the Ballroom, the Q&A session started.

I have a chance to post my questions as well. This is the summary that I have obtained.

  • The prepayment of plant and equipment (RM 19.9 M) is meant for the new injection plant.
  • Dr. Lee (MD) said that the new injection plant II will be ready by this year. Then, they will renovate the old injection plant. The management planned to build a line that can handle large batch size.
  • A shareholder mentioned that the product of YSPSAH is priced lower than competitor according to his survey. Nevertheless, Dr. Lee denied that and mentioned that his product is always priced higher than others (coz. better servicing). 
  • Dr. Lee mentioned that YSPSAH focuses mainly on private hospital, clinics and pharmacies. They market their products via building physical relations with customers to have good bonding with them (to build trust). Sometimes customers prefer to buy from YSPSAH as delivery is faster. However, for customers at some countries like Cambodia, they need an agent to help them coz it is too far.
  • A shareholder mentioned to me that YSPSAH is amongst the top sales company within the private healthcare sector.
  • Dr. Lee mentioned that the company revenue hardly grows since FY2024 because customers have frontloaded the medications during post-covid period. Plus, there is a upgrade in the operating facilities at Bangi plant (some old machines in the old injection plant is not functioning), hindering them to take more orders.


The Board gave each shareholder 1+1 door gift (SHINE brand supplements, consisting of probiotics, calcium pill, Vitamin pill). Why 1+1?? There is a shareholder requesting for extra supplement to be given out to each shareholder because there are many extra door gifts as many shareholders did not attend the meeting. Below is the door gift from YSPSAH during the AGM:


Meals include nasi goreng kampung, fried wanton, pastry and fruits. Taste so-so.. My wife ate only the pastry.


Overall, the Board has answered all my questions. I passed the marketing stretegies of Dr. Lee to Google AI and the AI told me this:


The management’s logic is based on a classic business trade-off: you cannot be the cheapest option and the highest-service option at the same time.
By avoiding government tenders, YSPSAH frees up the cash and resources needed to fund their expensive, high-touch private sector strategy.
Here is the direct linkage between the two decisions:
1. The Cost vs. Service Linkage
  • Government Tenders Demand Low Costs: Government contracts are won by bidding the absolute lowest price per pill. To survive on these razor-thin margins, a company must cut all extra costs. They cannot afford to spend money on a large sales force or fast, customized delivery fleets.
  • The Private Sector Demands Premium Service: Private clinics and pharmacies are willing to pay a higher price for medications if it means they get immediate delivery, flexible credit terms, and face-to-face relationship management.
  • The Strategic Link: If YSPSAH lowered its prices to win government tenders, it would lose the profit margins needed to pay for the fast delivery and physical relationship building that the private sector expects.

2. The Resource Allocation Linkage
  • A Dedicated Sales Fleet: Building physical relationships requires hiring, training, and fueling a massive team of sales representatives to visit thousands of individual clinics.
  • A Rapid Delivery Fleet: Providing fast delivery requires decentralized warehouses, local delivery drivers, and advanced tracking logistics.
  • The Strategic Link: Government buyers do not care about sales rep visits or 24-hour delivery; they buy in bulk months in advance. If YSPSAH spent its budget bidding on government tenders, it would not have the capital to invest in the sales reps and delivery trucks needed to win over private doctors.

Summary
The management is choosing margin over volume. They are walking away from low-profit government volume so they can reinvest their money into superior service, allowing them to charge premium prices to private clients.

Thursday, 30 April 2026

YSPSAH vs DPHARMA, which pharma company is better?

When it comes to choosing a listed pharmaceutical company to invest in Malaysia, most peoples would go for DPHARMA, or PHARMANIAGA. These names are popular, as both companies are able to secure huge government contracts to supply generic drugs to government hospitals.

Almost nobody would even bother (or aware) about this small pharmaceutical company in Malaysia, i.e. YSPSAH, especially during the recent years where its reporting net profit plummets. 

In this blog, I wish to compare YSPSAH against its competitor DPHARMA in various financial metrics.


(1) Reported and Core Profits

As shown in figure below, the reported net profit of YSPSAH is very unstable lately, while the reported net profit of DPHARMA is uptrending. No wonder many investors out there would prefer to have DPHARMA in their portfolios.



Let us pause for a little moment and analyze why YSPSAH's earnings is so fluctuative. 

According to the Management, its 30% of revenue is derived from overseas, which is dominated in USD. So, its reported earning would be subjected to the currency rate fluctuation (e.g. USD vs MYR) inevitably, depending on the forex rate when the invoice is issued to the foreign customers and the forex rate at the account closing date. I noticed that YSPSAH has reported quite a substantial amount of "unrealized" forex loss lately as below. As seen, the unrealized forex loss is at record high in year 2025 at RM 15M due to the stronger MYR against USD. Here is the key, all this forex loss is unrealized, which is yet converted to MYR. According to the Management, YSPSAH practices natural hedging so far, where the received USD would be used to purchase raw material in USD.



When analyzing the real operating performance of a company, the use of reported net profit is quite misleading sometimes, especially for those companies that are export-oriented. Core profit would be more useful in this regard. To get the core profit, I have added the unrealized forex loss to the reported net profit (Note that for unrealized forex gain, I would deduct it from the reported net profit instead). 

Figure below shows the reported and core profits of YSPSAH. In 2024 and 2025, there is a divergence in the trends of reported and core profits. In general, the core profit of YSPSAH is at record high in year 2025. Although the core business of YSPSAH is still performing well, Mr. Market has sent the share price of YSPSAH to its multi-year low level in 2025 as YPSAH's reported profit attributed to shareholders plummets due to huge amount of unrealized forex losses. This indicates that Mr. Market would pay more emphasis to reported profit as compared to core profit. This has in turn created a good opportunity for serious value investors out there to buy a good company at low price.




Meanwhile, the core profit of DPHARMA is almost similar to its reported profit attributed to shareholders as DPHARMA's business is mainly in Malaysia. In general, the uptrending pattern DPHARMA's profit is more consistent than YSPSAH, possibly due to consistent award of government contracts. For YSPSAH, in FY2024, only 13% of revenue is derived from government contracts.


(2) Gross Profit Margin & Core Profit Margin

API is the main raw material used in pharma industry. Nowadays, most likely, a pharma company would procure API from China (previously from Ukraine). Let us look into how well these 2 companies managing their material costs. Figure below shows the gross profit margin of YSPSAH and DPHARMA. Since 2017, YSPSAH outperforms DPHARMA in terms of gross profit margin. In FY2025, YSPSAH gross profit is around 44%, while DPHARMA is around 39%.



On the core profit margin, again, YSPSAH has outperformed DPHARMA in the most recent 4 years (2022-2025). YSPSAH experienced a drop in core profit margin during Covid period, which could be due to lock-down in overseas market.




(3) Return of Equity (ROE)

The ROE of DPHARMA is generally higher than that of YSPSAH as shown below. 


Let us analyze the ROE further by using the DuPont formula that breaks down ROE into three key drivers: 

(a) Profit Margin (Profitability) = Profit/Revenue 

(b) Asset Turnover (Efficiency) = Revenue/Total Asset

(c) Financial Leveraging (Leverage) = Total Asset/Total Equity


Profit margin (a) has been analyzed earlier. The core profit margin of YSPSAH in FY 2025 is larger than that of DPHARMA, as shown in previous section.


For (b) Efficiency:



YSPSAH is seemingly more efficient than DPHARMA in terms of asset turnover. 


For (c) Leverage:



Apparently, DPHARMA's ROE is higher than YSPSAH's because the financial leveraging of DPHARMA is relatively high, which is around 200%. The leverage of YSPSAH in year 2025 is only around 130%.


Why DPHARMA's leveraging is so high? It is found that DPHARMA has been borrowing quite a substantial amount to boost up its sales and profit. Note that its gearing (= total borrowing/equity) is as high as 65% in FY 2025 (see below), and it is ~ 6x higher than that of YSPSAH's gearing (~11% in 2025). In other words, YSPSAH is quite prudent in bank borrowing, and it is relying mainly on improving (a) Profit Margin (Profitability) and (b) Asset Turnover (Efficiency) to improve its ROE.




(4) Return of Invested Capital (ROIC)

K.C. Chong, a renowned value investor in Malaysia, has been advocating the use of ROIC to gauge the quality of a company in generating profits by using the total invested capital (including the use of debts). ROIC can be calculated as: ROIC = Core Operating Profit/Invested Capital, where Invested Capital = Inventory + Receivable - Payable + Fixed Asset. Fixed Asset consists of Property, Plant and Equipment (PPE), rights-of-use assets, etc. You may find more explanation about ROIC from his book.


Clearly, while YSPSAH's ROE is lesser than DPARMA's ROE, the ROIC of YSPSAH is apparently higher than that of DPHARMA, which could indicate that YSPSAH is better in managing the invested capital to generate profit.




(5) Free Cash Flow (FCF)

For a value investor, the main intention to invest in a company is to get consistent (and hopefully growing) dividends from a company. When dividend is growing, the share price would follow (hence capital gain). A good company would pay dividends from the generated free cash flow (FCF), not from bank borrowings. Figure below shows the FCF per share for YSPSAH and DPHARMA. Undoubtedly, YSPSAH is superior to DPHARMA in this regard. That could be the reason YSPSAH is able to pay high dividends to shareholders every year. At the current share price (RM 2.08, date: 1 May 2026), the dividend yield is ~ 5.3%.



(6) Historical PER

Figure below shows the historical PER (= Core Profit/Earnings Per Share). In general, DPHARMA commands a higher PER most of the time as it is one of the market's favourite. Its PER shoots to almost 40x during Covid period, possibly due to the vaccine supply. After 2020, its PER seems to normalize to pre-Covid level. YSPSAH, on the other hand, is currently trading at single digit PER, as it was experiencing a heavy sell-off in FY 2024 and FY 2025 after its reported profit drops significantly due to huge amount of unrealized forex loss. The low trading liquidity of YSPSAH is another reason why it could not attract big funds at the moment, leading to low PER.



Conclusion

(1) Core profit: DPHARMA shows a more stable uptrend of core profit, as compared to YSPSAH. YSPSAH's reported profit is bumpy due to forex fluctuation (30% export); however, its core profit is uptrending in general.

(2) Gross & Core profit margins: YSPSAH profit margins are relatively higher than those of DPHARMA.

(3) Return of Equity (ROE): The Return of Equity (ROE) of DPHARMA is higher than that of YSPSAH. Based on the DuPont analysis, the higher ROE of DPHARMA is due to its high financial leveraging. In other words, DPHARMA relies mainly on debts (or borrowings) to drive the business. The above observation can be supported by its high gearing of 65% in FY2025 (vs 11% in FY2025 for YSPSAH).

(4) Return of Invested Capital (ROIC): YSPSAH is more efficient than DPHARMA in using the invested capital to generate profit. The ROIC of YSPSAH in FY2025 is 16% (vs. DPHARMA of 13%)

(5) Free Cash Flow (FCF) per share: YSPSAH is generating significantly higher FCF per share (RM 0.36) than DPHARMA (RM 0.08).

(6) Historical PER: Valuation wise, YSPSAH is cheaper undoubtedly. Market seems to abandon YSPSAH most of the time, especially during the period when MYR is strengthening against USD. This is the period where YSPSAH will report significant forex loss. The key is that this forex loss is "unrealized".

Based on the above, it would give a clearer picture to my family members in selecting which company to invest in pharma industry in Malaysia. In the recent Annual Report 2025 of YSPSAH, I notice that Mr. Kong Goon Khing has emerged as one of the top 30 shareholders (5th largest shareholder). A quick fact find from Google suggests that Mr. Kong has owned other companies such as AEONCR,  HUMECMT, MNRB, etc. From his shareholdings, I believe Mr. Kong is a value investor.

During the AGM held in 2025, Dr. Lee (MD of YSPSAH) has mentioned that the company is constructing a new sterile line and he has expected that this line can start to operate in 2026. A huge prepayment of RM 19M has been allocated for PPE, as outlined in the Annual Report 2025. 


Thursday, 19 March 2026

Q4 2025 YSPSAH: A good quarter?

 


I am very lazy nowadays. Just have time to summarize the findings of YSPSAH recent quarter result. YSPSAH just reported its Q4 2025 earning as below:


As expected, due to the strengthening of MYR against USD, it booked another forex loss of RM 4M this quarter (vs. gain of RM 3 M Q4 2024). This reported figure is the combination of realized and unrealized forex loss. To know the exact numbers of each category, we have to refer to the upcoming annual report. No choice. However, according to my research (from FY2016 - FY2024), regardless of the fluctuation of USD against MYR, its realized forex gain/loss is only around RM 1M - 2M. I believe its natural hedging is properly implemented so far. Even during FY2024 (where USD weakens against MYR broadly), YSPSAH is still able to book in a realized forex gain of RM 1.6M (& unrealized loss of RM 9.2M).

For this Q42025, despite the forex loss, the net profit attributed to shareholders (accounting profit) stands at RM 7M, which is higher than the accounting profit reported in Q4 2024 (RM 6 M). On the whole year basis, however, the accounting profit for FY2025 is RM 25M, slightly lower than RM 27M made in FY2024. However, core profit (after adjusting forex loss, assuming the reported RM14M is unrealized forex loss) for FY 2025 is RM 39M (vs RM 35M in FY2024), which is commendable.




The operating cash flow (OCF) generated in FY 2025 is very strong, which is significantly higher than the accounting profit. Free cash flow in FY2025 comes at RM 54M-RM4M = RM 50M, which translate to FCF/share of RM0.35. It has ample cash to pay dividend from the internally generated cash flow obviously.

Concerning on its future expansion plan, I learn from the Management in AGM 2024 that they would build an advanced production line to boost up the capacity. They claimed that there is a problem in their old manufacturing line, leading to their inability to secure some local orders. As shown in the revenue breakdown below, local (and overall) sales experienced a slight drop indeed. This might indicate that the manufacturing plant could not take more capacity any longer, hence need further expansion.



From the cash flow statement (under Property, Plant and Equipment), I guess the number reported does not reflect the arrival of the new machinery yet. Still, the budget falls under capital commitment (Note A12 below). 



For valuation, core EPS comes at RM39M/142M shares = RM 0.27/share. Considering the closing price on 19/3/2026 (RM2.08), PER ~ 7.7. Personally, I found that it is very attractive. Plus, its dividend yield is > 5% with potential of further profit growth after the commissioning of the new production line.


Of course, Mr. Market would definitely abandon this counter as the USD is weakening nowadays (vs MYR). For a value investor like me, this would enable me to slowly accumulate the shares. Of course, this comes at certain opportunity cost. However, I am the kind of person that do not like to chase hot counter at high valuation. This kind of "boring" counter, instead, is my cup of tea.


The risk is rising energy cost (Iran war) and competition from bigger rival like DPHARMA in local market. It seems to me that DPHARMA is always the preferred supplier of government hospital. The Management told me that their competitiveness is their good service. Well, I am not sure how good service would translate to more sales lah... I am not familiar in pharma industry. Need more time to find out.

Friday, 9 January 2026

Ringgit is getting stronger vs. USD in 2025 – Impact on YSPSAH

 

Not many peoples are aware of this pharmaceutical company that manufactures generic drugs, i.e., YSPSAH that was established in Malaysia since 1987. It is a Taiwanese pharmaceutical company based in Bangi, Selangor. The company was listed in KLSE since 2004.


From the annual report 2024 of YSPSAH, the overseas revenue consists of almost 30% of the total revenue reported. Indeed, the weightage of overseas sales is quite heavy as compared to its competitors. I think it is part of the strategy of the management team, as they are aware that Malaysian market is relatively small as compared to other ASEAN countries and the local market is dominated by bigger players such as DPHARMA and AHEALTH.

 

But why this company grasps my attention? Firstly, it is cheap, not in price though, but in terms of valuation. Secondly, the traded share price on 19 Dec 2025 is discounted at almost 28% from its book value. Thirdly, strong operating and free cash flows, allowing the company to pay consistent dividend. At the time of writing, the traded share price is RM2.09, which translates to RM0.11/RM2.09 = 5.3% dividend yield.

 

The historical share price of YSPSAH (up to 19 Dec 2025) is shown below:

Figure 1: Historical share price of YSPSAH

Why is its share price plunging since June 2024? Well, I believe it is due to the cutting of interest rate in the US, thus weakening the USD against other currencies. From June 2024 to Dec 2025 (time of writing), USD has weakened against MYR from RM4.7/USD to RM 4.08/USD. See below:

 

Figure 2: USD to MYR rate

 

As an export-based pharmaceutical company like YSPSAH, foreign exchange loss is inevitable in the current condition. The foreign exchange loss would appear in the income statement (e.g. in Other Expenses), decreasing the reported bottom line (profit attributed to shareholder). The historical reported profit attributed to shareholder of YSPSAH looks like this:

Figure 3: Reported profits of YSPSAH

 

As seen from Figure 3 above, the reported profits experienced a more apparent fluctuation since 2016. However, do note that the reported profit has included non-cash item such as unrealized foreign exchange (forex) loss. As it is a non-cash item, it should be added back to the reported earning in Figure 3 to come out with the “core profit” of the company, which can provide a clearer, more consistent picture of a company's ongoing, primary business health. The historical core profit (after adding/deducting the forex loss/gain, respectively, with the reported profit) is shown below:

Figure 4: Core profits (after including the effect of unrealized forex gain/loss) of YSPSAH

 

As shown in Figure 4, the core profit is trending upwards generally, except during the Covid lock-down period. So, based on Figure 4, I believe that the core business of YSPSAH is still growing.

 

So, now we know the business of YSPSAH is still doing fine. The next question is its valuation. Can we accumulate the shares?

 

Following the approach of HLIB in valuing DKSH, the fair PE ratio (PER) based on core earnings per share (core EPS) is used. The historical PER based on core EPS, or the core PER, is shown in Figure 5 (last sub-figure at the bottom). 

Figure 5: Selection of core PER values

Averaging Process: Use of 5-year average PER to estimate the fair PER of a company

Many investors, including my respected investment guru (cold eye) advocated the use of 5-year average PER (some used median value) as the method to estimate the fair PER of a company. It is one of the relative valuation methods which is quite helpful. However, in 2024 (and even 2025), the share price of YSPSAH is depressed (due to low reported earnings, see Figures 1 & 3) regardless of the strengthening of its core profit (Figure 2). Hence, the core PER value of YSPSAH in 2024 is relatively low, which might not reflect the true valuation of the company. On the  other hand, in 2021, the core PER is very high as the company reported very weak earnings during the Covid period. 


Therefore, instead of taking the core PER directly from the most recent 5-years  (as what most peoples did) for the averaging process, the PER values used to perform the averaging must be selected carefully to get the fair PER of a company, from my point of view. My modified criterion is below:


To get the averaged core PER of a company, the core PER values should be obtained only from those years where both reported and core earnings are trending upward year on year. This is to make sure there is a close valuation alignment between the market perception (mainly based on reported EPS) and the core business operation (based on core EPS).


The core PER values that satisfy the above criterion is highlighted in the red box shown in Figure 5, obtained from years 2013, 2015, 2018 and 2022. Averaging the core PER values from these years, the mean and median values are around 12.35 and 11.94, respectively. One may set the fair core PER of YSPSAH at 11.94 (on the conservative side).

 

The reported core EPS in year 2024 is RM 0.25. Based on the closing price as of 19 Dec 2025 (RM 2.09), the core PER is currently at 8.36 merely, a very undemanding valuation. The margin of safety [MOS = (11.94-8.36)/8.36] is around 43%!!

 

Is it a safe bet? 

In terms of valuation, it is very attractive obviously. However, as long as USD stays weak against MYR, I believe the market would not favour YSPSAH, although the core profit is strong. Nevertheless, this might be a good opportunity for any value investors out there to accumulate the shares of a good company at a cheap price, isn’t it? As value investors, our role is to merely monitor its core earning and ensure it stays resilient.